Source: Eur Respir Rev, 28 (154) 190095; 10.1183/16000617.0095-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mario Cazzola, Paola Rogliani, Maria Gabriella Matera. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev, 28 (154) 190095; 10.1183/16000617.0095-2019

Member's Comments

No comment yet.

Related content which might interest you: Are bronchodilator drugs really useful in COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001 Is it time to move away from short-acting beta-agonists in asthma management? Source: Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018 Year: 2019 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Therapeutic approaches beyond positive airway pressure and bronchodilators: time for rehabilitation? Source: Sleep and Breathing Conference 2021 Year: 2021 A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 Source: Eur Respir J 2013; 42: 972-981 Year: 2013 Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009 An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 Inhaled beta2-agonists in asthma management: an evolving story Source: Breathe 2016; 12: 375-377 Year: 2016 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Anti-asthmatic drugs: treatment of athletes and exercise-induced bronchoconstriction Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-22-7, page=73 Year: 2005 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Inhaled therapies: can they breathe new life into asthma? Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Inhaler preference comparing two alternative dual bronchodilator regimens Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006